Evidence map›Paper›PMID 37594630›Full record

ArticleCellular and molecular life sciences : CMLS2023

Protease-independent control of parthanatos by HtrA2/Omi.

Jonas Weiß, Michelle Heib, Thiemo Korn, Justus Hoyer, Johaiber Fuchslocher Chico, Susann Voigt, Tomas Koudelka, Andreas Tholey, Dieter Adam

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jonas WeißInstitut für Immunologie, Christian-Albrechts-Universität zu Kiel, Michaelisstr. 5, 24105, Kiel, Germany.
Michelle HeibInstitut für Immunologie, Christian-Albrechts-Universität zu Kiel, Michaelisstr. 5, 24105, Kiel, Germany.
Thiemo KornInstitut für Immunologie, Christian-Albrechts-Universität zu Kiel, Michaelisstr. 5, 24105, Kiel, Germany.
Justus HoyerInstitut für Immunologie, Christian-Albrechts-Universität zu Kiel, Michaelisstr. 5, 24105, Kiel, Germany.
Johaiber Fuchslocher ChicoInstitut für Immunologie, Christian-Albrechts-Universität zu Kiel, Michaelisstr. 5, 24105, Kiel, Germany.
Susann VoigtInstitut für Immunologie, Christian-Albrechts-Universität zu Kiel, Michaelisstr. 5, 24105, Kiel, Germany.
Tomas KoudelkaInstitut für Experimentelle Medizin, Christian-Albrechts-Universität zu Kiel, Niemannsweg 11, 24105, Kiel, Germany.
Andreas TholeyInstitut für Experimentelle Medizin, Christian-Albrechts-Universität zu Kiel, Niemannsweg 11, 24105, Kiel, Germany.
Dieter AdamInstitut für Immunologie, Christian-Albrechts-Universität zu Kiel, Michaelisstr. 5, 24105, Kiel, Germany. dadam@email.uni-kiel.de.ORCID http://orcid.org/0000-0002-5668-5032
Christian-Albrechts-Universität zu Kiel · DE

Funding

Deutsche Forschungsgemeinschaft 125440785 - SFB 877Deutsche Forschungsgemeinschaft Project B2
6 · The paper itself

Abstract

HtrA2/Omi is a mitochondrial serine protease with ascribed pro-apoptotic as well as pro-necroptotic functions. Here, we establish that HtrA2/Omi also controls parthanatos, a third modality of regulated cell death. Deletion of HtrA2/Omi protects cells from parthanatos while reconstitution with the protease restores the parthanatic death response. The effects of HtrA2/Omi on parthanatos are specific and cannot be recapitulated by manipulating other mitochondrial proteases such as PARL, LONP1 or PMPCA. HtrA2/Omi controls parthanatos in a manner mechanistically distinct from its action in apoptosis or necroptosis, i.e., not by cleaving cytosolic IAP proteins but rather exerting its effects without exiting mitochondria, and downstream of PARP-1, the first component of the parthanatic signaling cascade. Also, previously identified or candidate substrates of HtrA2/Omi such as PDXDC1, VPS4B or moesin are not cleaved and dispensable for parthanatos, whereas DBC-1 and stathmin are cleaved, and thus represent potential parthanatic downstream mediators of HtrA2/Omi. Moreover, mass-spectrometric screening for novel parthanatic substrates of HtrA2/Omi revealed that the induction of parthanatos does not cause a substantial proteolytic cleavage or major alterations in the abundance of mitochondrial proteins. Resolving these findings, reconstitution of HtrA2/Omi-deficient cells with a catalytically inactive HtrA2/Omi mutant restored their sensitivity against parthanatos to the same level as the protease-active HtrA2/Omi protein. Additionally, an inhibitor of HtrA2/Omi's protease activity did not confer protection against parthanatic cell death. Our results demonstrate that HtrA2/Omi controls parthanatos in a protease-independent manner, likely via novel, unanticipated functions as a scaffolding protein and an interaction with so far unknown mitochondrial proteins.

Indexed as

ParthanatosMitochondrial ProteinsNecroptosisSerine EndopeptidasesSerine ProteasesMitochondrial ProteinsSerine EndopeptidasesSerine ProteasesCell deathHtrA2/OmiParthanatosProteolysis

Identifiers

PMID37594630
PMCPMC10439076
OpenAlexW4385968551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.